CD8A and neoplasm: Treatment with PD-1/PD-L1 ICIs can be prescribed based on tumor biomarkers including PD-L1 expression, tumor mutation burden (TMB), CD8+ T cell infiltration, microsatellite instability (MSI) [71], and TCR clonality [72].